== Study Objectives ==
 The aim of this study is to explore the efficacy and safety of the combination of Lanreotide ATG 120 mg and TMZ 
 in progressive T-NETs .  Lanreotide ATG 120 mg in combination with TMZ 250 mg for a treatment period of 52 weeks . 
 Number of subjects planned: 40 subjects with progressive well or moderately differentiated thoracic neuroendocrine 
 tumors (lung and thymic carcinoids) Diagnosis and criteria for inclusion: Inclusion Criteria: 1) Provision of written 
 Informed Consent prior to any study related procedures .

